BOLD

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

High

1.320

Open

1.280

VWAP

Vol

94.88K

Mkt Cap

27.76M

Low

1.200

Amount

EV/EBITDA(TTM)

Total Shares

22.39M

-109.94M

EV/OCF(TTM)

P/S(TTM)

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.733

-4.76%

-0.520

-29.73%

-0.510

-31.08%

Estimates Revision

Stock Price

Go Down

-22.50%

In Past 3 Month

3 Analyst Rating

222.58% Upside

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

222.58% Upside

Current: 1.240

Low

3.00

Averages

4.00

High

5.00

222.58% Upside

Current: 1.240

Low

3.00

Averages

4.00

High

5.00

Goldman Sachs

Richard Law

initiated

2025-07-24

New

Reason

Goldman Sachs

Richard Law

Price Target

2025-07-24

New

initiated

Reason

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio with an Early-Stage Biotech rating, saying the company's combo approach for its lead asset BBI-355 comes with high risk.

H.C. Wainwright

NULL -> Buy

initiated

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

initiated

NULL -> Buy

Reason

Leerink

Outperform -> Market Perform

downgrade

$15 -> $3

2025-05-27

Reason

Leerink

Price Target

$15 -> $3

2025-05-27

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Boundless Bio to Market Perform from Outperform with a price target of $3, down from $15. The company is discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial based on a narrow therapeutic index observed with dosing, the analyst tells investors in a research note. The firm is moving to the sidelines pending validation of Boundless Bio's new approach. It removed all value for the CHK1 program until the company validates the BBI-355 and BBI-825 combination hypothesis in specific tumor types.

Guggenheim

Yige Guo

Strong Buy

Hold

Downgrades

n/a

2024-12-13

Reason

Guggenheim

Yige Guo

Price Target

n/a

2024-12-13

Downgrades

Strong Buy

Hold

Reason

Guggenheim analyst Michael Schmidt downgraded Boundless Bio to Neutral from Buy.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Boundless Bio Inc (BOLD.O) is -0.54, compared to its 5-year average forward P/E of -1.15. For a more detailed relative valuation and DCF analysis to assess Boundless Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.15

Current PE

-0.54

Overvalued PE

-0.23

Undervalued PE

-2.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.40

Current EV/EBITDA

1.35

Overvalued EV/EBITDA

2.05

Undervalued EV/EBITDA

-2.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00